Loading ...
Biotrofix These studiesledto a successful Phase II clinical trial in chronic stroke patients
In clinical and preclinical ischaemic stroke studies , COX-1 metabolites have been shownto contributeto injury during the chronic phase of stroke [ 53,54
The system allowsto designpersonalized training sessions from the acute through to the chronic stage of patients ' recovery
intensive rehabilitation therapyresultedin behavioural gains for patients with chronic hemiparetic stroke
severe gait disorderresultingfrom an ischaemic stroke in the chronic phase of rehabilitation
the ability of PNS applied to the ( 1 ) arm , ( 2 ) leg , and ( 3 ) idle timeto influencetraining effects in the paretic hand in 7 chronic stroke patients
the pressing needto preventpatients from going from chronic - phase disease into accelerated phase / blast crisis
difference in sandy ground between firm groundinfluencesthe effects of gait training in patients with chronic stroke
imatinib ... to failto preventthe onset of lymphoid transformation in patients in chronic phase
to atypical movement patterns and compete with subsequent neural reorganization during later trainingcontributeto atypical movement patterns and compete with subsequent neural reorganization during later training
to a trend of improvement in clinical and functional magnetic resonance imaging ( fMRI ) scores at 8 weeksledto a trend of improvement in clinical and functional magnetic resonance imaging ( fMRI ) scores at 8 weeks
a wide variance between time of stroke , duration of symptoms , and timing of treatmentcreatinga wide variance between time of stroke , duration of symptoms , and timing of treatment
to remodeling of the residual motor network ( 14 ... and promote motor recovery more effectively than a further loss of inhibition ( 13may contributeto remodeling of the residual motor network ( 14 ... and promote motor recovery more effectively than a further loss of inhibition ( 13
to an increase in cortical activity in addition to evident motor recoverywould leadto an increase in cortical activity in addition to evident motor recovery
in the majority of patients achieving a major molecular response after 2 years of therapyresultingin the majority of patients achieving a major molecular response after 2 years of therapy
therapy witha standard dose of imatinib for 12 monthsleadstherapy witha standard dose of imatinib for 12 months
to identify the sensitivity of common outcome measuresdesignedto identify the sensitivity of common outcome measures
in little or no difference in rate of falls ( rate ratio 0.58 , 95 % CI 0.31 to 1.12 , 205 participantsresultedin little or no difference in rate of falls ( rate ratio 0.58 , 95 % CI 0.31 to 1.12 , 205 participants
in a response in 45 % of patientsresultedin a response in 45 % of patients